JAK抑制剂或bDMARD治疗与荷兰类风湿关节炎人群心血管事件风险
在荷兰类风湿关节炎人群中,比较JAK抑制剂与bDMARD使用者心血管事件发生率,共纳入15191例患者、28481患者年,JAKi组36例事件(1.52例/100患者年)对比bDMARDs组383例事件(1.47例/100患者年),调整后IRR为0.99(95%CI 0.70, 1.41)。结论认为风险似乎无差异,但不能排除高危患者中小幅增加的可能。
要点
- JAKi组心血管事件密度1.52例/100患者年,bDMARDs组1.47例/100患者年,调整后IRR 0.99(95%CI 0.70, 1.41)。
- >65岁、按性别及托法替布与巴瑞替尼分别分析的亚组结果相似。
- 作者结论认为JAKi与bDMARDs的心血管事件风险似乎无差异,但不能排除高危患者中小幅增加。
核心结论
- 在荷兰大型类风湿关节炎普通人群中,JAKi使用者与bDMARDs使用者的心血管事件风险似乎无差异,尽管不能排除较高危患者中的小幅增加。
研究设计与样本
- 从IQVIA荷兰真实世界数据纵向处方数据库(覆盖荷兰约63%的门诊处方)中选取2018年8月1日至2022年1月31日期间开始新bDMARD或JAKi治疗的类风湿关节炎患者。
- 共纳入15191例独特患者,28481患者年治疗时间,其中JAKi组2373患者年、bDMARDs组26108患者年;多数为女性(72%),中位年龄62岁。
- 研究结局为心血管事件,定义为研究期间开始使用血小板聚集抑制剂;采用多水平泊松回归比较JAKi与bDMARDs的心血管事件发生密度,并调整暴露时间和混杂因素。
主要发现
- JAKi治疗期间发生36例心血管事件(1.52例/100患者年),bDMARDs治疗期间发生383例事件(1.47例/100患者年)。
- 与bDMARDs相比,JAKi的调整后发病率比(IRR)为0.99(95%CI 0.70, 1.41)。
- 在>65岁患者、按性别分析、以及托法替布和巴瑞替尼分别分析的亚组中,结果相似。
关键数值与推荐
- JAKi组心血管事件发生密度为1.52例/100患者年,bDMARDs组为1.47例/100患者年。
- JAKi对比bDMARDs的调整后IRR为0.99(95%CI 0.70, 1.41)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者结论指出,不能排除较高危患者中心血管事件风险的小幅增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Caution has been advocated recently when using Janus kinase inhibitors (JAKi) in rheumatoid arthritis (RA) patients with an unfavourable cardiovascular risk profile. We aimed to compare the incidences in cardiovascular events between JAKi and biologic DMARDs (bDMARDs) in a large population of RA patients. METHODS: RA patients starting a new bDMARD or JAKi between 1 August 2018 and 31 January 2022 have been selected from IQVIA's Dutch Real-World Data Longitudinal Prescription database, covering about 63% of outpatient prescriptions in the Netherlands. Study outcome was a cardiovascular event, defined as the start of platelet aggregation inhibitors during the study period. The incidence densities of cardiovascular events were compared between JAKi and bDMARDs using multilevel Poisson regression, adjusted for exposure time and confounders. RESULTS: The number of unique patients included was 15 191, with 28 481 patient-years on treatment with either JAKi (2373) or bDMARDs (26 108). Most patients were female (72%) and median age was 62 years. We found 36 cardiovascular events (1.52 events/100 patient-years) during therapy with JAKi and 383 events (1.47 events/100 patient-years) during therapy with bDMARDs, resulting in an adjusted incidence rate ratio (IRR) of 0.99 for JAKi compared with bDMARDs (95% CI: 0.70, 1.41). Sub-analyses in patients >65 years, by sex, or separately for tofacitinib and baricitinib, yielded similar results. CONCLUSION: In a large Dutch general RA population, the risk of cardiovascular events seems not to be different between JAKi users and those using bDMARDs, although a small increase in higher risk patients cannot be excluded.
引用
- Popa CD, Opdam MAA, den Broeder N, et al. Therapy with JAK inhibitors or bDMARDs and the risk of cardiovascular events in the Dutch rheumatoid arthritis population. Rheumatology (Oxford). 2024. PMID: 37796830. doi:10.1093/rheumatology/kead531
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。